Literature DB >> 34950395

Case Report: Opsoclonus-Myoclonus Syndrome Associated With Contactin-Associated Protein-Like 2 and Acetylcholine Receptor Autoantibodies in the Setting of Non-Small Cell Lung Carcinoma.

Christian S Rosenow1, Sara Dawit2, Luca P Farrugia1, Katharine A Henry Ma1, Akanksha Sharma2, Andrew McKeon2, Alyx B Porter2, Marie F Grill2.   

Abstract

Opsoclonus myoclonus syndrome (OMS) is a rare immune-mediated paraneoplastic or para/-post-infectious syndrome characterized by "dancing" eye movements, myoclonus, and ataxia. Neuropsychiatric symptoms have also been reported. Without treatment, OMS may progress to further neurological impairment and even death. Autoimmune attack of CNS structures in OMS is most commonly mediated by anti-Ri (also known as ANNA2) IgG antibodies, with additional findings implicating antibodies targeting various neurotransmitter receptors. Prompt immunotherapy and neoplasm treatment may result in improvement. We report a novel association of Contactin-Associated Protein-Like 2 (Caspr2) antibodies occurring in association with paraneoplastic OMS. While breast cancer and small cell lung cancer (SCLC) are more commonly associated with OMS among adults, we characterize a novel association between Caspr2 antibody in a patient with mixed non-small cell and small cell lung carcinoma.
© The Author(s) 2021.

Entities:  

Keywords:  autoimmune diseases of the nervous system; clinical specialty; cranial nerve diseases; nervous system; nervous system neoplasms; neuroimmunology; neurooncology; opsoclonus-myoclonus syndrome; paraneoplastic syndromes

Year:  2021        PMID: 34950395      PMCID: PMC8689548          DOI: 10.1177/19418744211012899

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  23 in total

1.  Effective high-dose clonazepam treatment in two patients with opsoclonus and myoclonus: GABAergic hypothesis.

Authors:  Ales Bartos
Journal:  Eur Neurol       Date:  2006-10-20       Impact factor: 1.710

Review 2.  Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome.

Authors:  Mark P Gorman
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

3.  Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies.

Authors:  S Vernino; P A Low; R D Fealey; J D Stewart; G Farrugia; V A Lennon
Journal:  N Engl J Med       Date:  2000-09-21       Impact factor: 91.245

4.  Opsoclonus-Myoclonus Syndrome: A New Era of Improved Prognosis?

Authors:  Armine Galstyan; Colin Wilbur; Kathryn Selby; Juliette Hukin
Journal:  Pediatr Neurol       Date:  2017-03-27       Impact factor: 3.372

5.  Correlation of clinical improvement with pontine lesions in opsoclonus-myoclonus syndrome.

Authors:  T Tsutada; T Izumi; T Murakami
Journal:  Osaka City Med J       Date:  1996-07

6.  Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies.

Authors:  Thaís Armangué; Lidia Sabater; Estefanía Torres-Vega; Eugenia Martínez-Hernández; Helena Ariño; Mar Petit-Pedrol; Jesús Planagumà; Luis Bataller; Josep Dalmau; Francesc Graus
Journal:  JAMA Neurol       Date:  2016-04       Impact factor: 18.302

7.  Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome.

Authors:  Elizabeth D Tate; Tyler J Allison; Michael R Pranzatelli; Steven J Verhulst
Journal:  J Pediatr Oncol Nurs       Date:  2005 Jan-Feb       Impact factor: 1.636

8.  Long-term survival in paraneoplastic opsoclonus-myoclonus syndrome associated with small cell lung cancer.

Authors:  Khaled A Hassan; Gregory P Kalemkerian; Jonathan D Trobe
Journal:  J Neuroophthalmol       Date:  2008-03       Impact factor: 3.042

9.  Immune or Genetic-Mediated Disruption of CASPR2 Causes Pain Hypersensitivity Due to Enhanced Primary Afferent Excitability.

Authors:  John M Dawes; Greg A Weir; Steven J Middleton; Ryan Patel; Kim I Chisholm; Philippa Pettingill; Liam J Peck; Joseph Sheridan; Akila Shakir; Leslie Jacobson; Maria Gutierrez-Mecinas; Jorge Galino; Jan Walcher; Johannes Kühnemund; Hannah Kuehn; Maria D Sanna; Bethan Lang; Alex J Clark; Andreas C Themistocleous; Noboru Iwagaki; Steven J West; Karolina Werynska; Liam Carroll; Teodora Trendafilova; David A Menassa; Maria Pia Giannoccaro; Ester Coutinho; Ilaria Cervellini; Damini Tewari; Camilla Buckley; M Isabel Leite; Hendrik Wildner; Hanns Ulrich Zeilhofer; Elior Peles; Andrew J Todd; Stephen B McMahon; Anthony H Dickenson; Gary R Lewin; Angela Vincent; David L Bennett
Journal:  Neuron       Date:  2018-02-08       Impact factor: 17.173

10.  Glutamate receptor δ2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome.

Authors:  Georgina Berridge; David A Menassa; Teresa Moloney; Patrick J Waters; Imogen Welding; Selina Thomsen; Sameer Zuberi; Roman Fischer; A Radu Aricescu; Michael Pike; Russell C Dale; Benedikt Kessler; Angela Vincent; Ming Lim; Sarosh R Irani; Bethan Lang
Journal:  Neurology       Date:  2018-07-25       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.